17 September,2024 12:12 PM IST | New Delhi | IANS
Image for representational purpose only. Photo Courtesy: istock
Even as injectable weight loss drugs have become a popular option for people struggling with obesity, 1 in 4 or 25 per cent consider using them without consulting their doctor, exposing themselves to several health risks, finds a study on Tuesday.
Cost and lack of insurance coverage are some reasons for seeking prescription alternatives, said the team from The Ohio State University, US, who surveyed 1,006 adults in America.
"Some people are skipping the doctor's office and reaching out to potentially unreliable sources such as unlicensed online pharmacies or telehealth sites, which could expose patients to risks," the team said.
Cost (18 per cent) is the major reason identified in the survey, followed by not being covered by insurance (15 per cent), inability to get a prescription from their doctor (9 per cent), and lack of availability through a pharmacy (6 per cent).
ALSO READ
Gujarat confirms fourth HMPV case as nine-month-old tests positive
Skincare expert Blossom Kochhar shares beauty tips, recipes in new book
IIT Kanpur develops unique robotic hand exoskeleton for stroke rehabilitation
Men are three times more likely to die from a brain injury: Study
Actor Tiku Talsania suffers heart attack, condition critical: Reports
"It's really important for those who want to lose weight to first discuss options with their doctor. It is not one size fits all, and every medication can have risks and side effects," said Shengyi Mao, an Ohio State internal medicine physician.
Mao said doctors will "go through a patient's medical history" and prescribe medications by assessing "their particular risks and benefits".
Recently developed weight loss drugs called GLP1-RA (with brand names Ozempic and Wegovy) help in weight loss because they can curb appetite and slow emptying of the stomach.
The medication which comes with Semaglutide salt has been approved by the US FDA for reducing cardiovascular risk in adults who are overweight or obese and have established cardiovascular disease.
But the regulator also issued two warnings about compounded Semaglutide including reports of dosing errors resulting in hospitalisation and ineffective ingredients.
Compounded drugs are custom-made alternatives to brand names and made in state-licensed pharmacies instead of by drug manufacturers when a drug is in short supply.
Mao said "Obesity is a serious and complex chronic disease" and should be addressed by a "comprehensive weight management programme".
"These weight loss drugs may be effective for some people but they can cause serious side effects and the weight may return after they stop taking them."
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.